Tag Archives: Boris Peaker

Nucana Plc Receives a Buy from Cowen & Co.

Cowen & Co. analyst Boris Peaker assigned a Buy rating to Nucana Plc (NASDAQ: NCNA) today. The company’s shares opened today at $27.25, close to its 52-week high of $30.41. According to TipRanks.com, Peaker is a 5-star analyst with an

Analysts Conflicted on These Healthcare Names: ImmunoGen (NASDAQ: IMGN) and Agios Pharma (NASDAQ: AGIO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on ImmunoGen (NASDAQ: IMGN) and Agios Pharma (NASDAQ: AGIO). ImmunoGen (NASDAQ: IMGN) Cowen & Co. analyst Boris Peaker assigned a Hold rating to ImmunoGen (NASDAQ: IMGN)

Cowen & Co. Believes Urogen Pharma Ltd (NASDAQ: URGN) Still Has Room to Grow

In a report released today, Boris Peaker from Cowen & Co. maintained a Buy rating on Urogen Pharma Ltd (NASDAQ: URGN). The company’s shares opened today at $60.14, close to its 52-week high of $66.38. According to TipRanks.com, Peaker is

Surface Oncology Inc Initiated with a Buy at Cowen & Co.

In a report released today, Boris Peaker from Cowen & Co. initiated coverage with a Buy rating on Surface Oncology Inc (NASDAQ: SURF). The company’s shares opened today at $13.39. According to TipRanks.com, Peaker is a 5-star analyst with an

Cowen & Co. Keeps Their Buy Rating on CytomX Therapeutics Inc

In a report released yesterday, Boris Peaker from Cowen & Co. maintained a Buy rating on CytomX Therapeutics Inc (NASDAQ: CTMX). The company’s shares opened today at $22.79. According to TipRanks.com, Peaker is a 5-star analyst with an average return

Cowen & Co. Maintains Their Hold Rating on Proteon

In a report released yesterday, Boris Peaker from Cowen & Co. maintained a Hold rating on Proteon (NASDAQ: PRTO). The company’s shares opened today at $2.10. According to TipRanks.com, Peaker is a 5-star analyst with an average return of 17.3%